Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.

Also called NCT01055912

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 170 participants (enrolled count) (from the registry)
Sponsor
CardioKine Inc. (from the registry)
Registry
  • NCT NCT01055912
Other papers using this trial's data
  • The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study European journal of heart failure, 2012-06 DOI, PubMed 22510424

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01055912. Randomized; triple masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure
Condition
Congestive Heart Failure
Intervention (Drug)
Lixivaptan
Intervention (Drug)
Placebo
Lead sponsor
CardioKine Inc. (class: industry)
Collaborator
Cardiokine Biopharma, LLC (class: industry)

Record details

Record id
cardio:ct-nct01055912
Content hash
2a9630672b9590d6898b7cb74f1e5d985f5ec0739a05c68c0c75ed4728546b95